Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-213 in Iron-deficiency Anemia
NCT02828319Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoints: Number of participants with Adverse Drug Reactions at 12 weeks and Number of participants with Adverse Events at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02828319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828319.